News

SEC ends probe of Illumina’s Grail acquisition
The DNA sequencing company also cut its 2025 earnings outlook to reflect the impact of tariffs on its business.
Q1 2025 Illumina Inc Earnings Call
Good day, ladies and gentlemen, and welcome to the first-quarter 2025 Illumina earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would ...
In Vitro Diagnostics Market worth US$157,632.5 million by 2030 with 7.6% CAGR | MarketsandMarkets
The global In Vitro Diagnostics Market, valued at US$100,769.3 million in 2024, is forecasted to grow at a robust CAGR of 7.6%, reaching US$109 ...
Standard BioTools Inc.: Standard BioTools Reports First Quarter 2025 Financial Results
Standard BioTools Inc. (NASDAQ: LAB) (the "Company" or "Standard BioTools") today announced financial results for the first quarter ended ...
Bio-Rad: With Low Debt And A Stock Price Drop, Is The Company Undervalued?
Ooops... Something went wrong while loading this page.
US close: Stocks mostly lower as traders look ahead to China talks
Major indices were mostly lower at the close of trading on Friday as market participants looked ahead to talks with Chinese ...
US open: Stocks cautiously higher ahead of China talks
Major indices were slightly higher at the open on Friday as traders looked ahead to talks with Chinese officials over the ...
moneycontrol.com22h
Texas Instruments
Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...